2025 Updates in Care of the Hematologic Malignancies Patient: with Proceedings from International Medical Meetings

LIVECMECNE

Add to Calendar 2025 Updates in Care of the Hematologic Malignancies Patient: with Proceedings from International Medical Meetings 1/17/2025 7:00:00 AM 1/17/2025 4:00:00 PM America/New_York For More Details: https://upenn.cloud-cme.com/course/courseoverview?EID=91314 Description: This course is a comprehensive review of hematologic malignancies focusing on research developments over the preceding year and their application to the patient care journey. Didactic presentations will include case discussion with Penn faculty and community experts. Activity format will provide significant opportunity for interaction with expert faculty and other attendees with the aim of implementing... Hilton Hotel Philadelphia City Avenue false MM/DD/YYYY


Friday, January 17, 2025, 7:00 AM - 4:00 PM, Hilton Hotel Philadelphia City Avenue, Philadelphia, PA


This course is a comprehensive review of hematologic malignancies focusing on research developments over the preceding year and their application to the patient care journey. Didactic presentations will include case discussion with Penn faculty and community experts. Activity format will provide significant opportunity for interaction with expert faculty and other attendees with the aim of implementing new standards of patient care. Participants will leave with up-to-date, practical information which will have immediate clinical application.


Specialties - CLINICAL GENETICS AND GENOMICS (MD), INTERNAL MEDICINE - Hematology, PEDIATRICS - Pediatric Hematology-Oncology


Objectives

After completing this activity, participants should be able to:


  1. Evaluate evolving treatment strategies for mantle cell lymphoma.
  2. Explain equal access to transplant and the use of mismatched donors
  3. Describe cell therapy approaches for autoimmune diseases.
  4. Analyze progress in GVHD therapies.
  5. Evaluate emerging treatment options for AML.
  6. Apply current management of MDS and bone marrow failure syndromes.
  7. Summarize updates in CML and myeloproliferative disease.
  8. Analyze current and future immunotherapies for acute leukemias (including CD33 CAR T-cell therapy).
  9. Explain current approaches to smoldering myeloma and amyloidosis.
  10. Review initial therapy for multiple myeloma, including the role of transplant.
  11. Evaluate the role of immunotherapy in myeloma treatment.
  12. Analyze investigational therapies for relapsed myeloma.


In support of improving patient care, Penn Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.  

Designation of Credit



AMA PRA Category 1 Credits™ (7.25 hours), NCPD Hours (ANCC) (7.25 hours), Non-Physician Attendance / Participation (7.25 hours)